Introduction of department
Radiation Oncology Department at Hiroshima University Hospital is one of the largest radiation therapy facilities in west Japan. We have 7 certificated radiation oncologists specialized in lung, esophagus, breast, head & neck, prostate, brain and other cancer treatments. Our primary goal is to provide high quality expert service to the cancer patients. Our department has started intensity-modulated radiation therapy (IMRT) in 2008 and introduced the newest IMRT technique “volumetric-modulated arc therapy (VMAT)” in 2010. We have also developed the image-guided radiation therapies (IGRT) to improve the clinical outcomes with minimizing the adverse effects. We also actively provide stereotactic body radiotherapy (SBRT) which permits millimeters order precision for lung and liver cancers.
We have started the new treatments including VMAT for thoracic esophageal cancers, image-guided brachytherapy (IGBT) for uterine cervical cancers and high-dose-rate brachytherapy for oral cancers.
JCOG 1208: A non-randomized confirmatory study of intensity modulated radiation therapy for T1-2N0-1M0 oropharyngeal cancer
JCOG 1408: A randomized phase III trial oｆ comparing two dose-fractionations stereotactic body radiotherapy for medically inoperable stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer
JROSG10-2: A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal.
JCOG 1510: A phase 3 study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus.
JCOG1008: Phase II/III Trial of Postoperative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck
JCOG1212: Dose finding and confirmatory trial of superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for patients with locally advanced maxillary sinus cancer
JCOG1016: Phase III randomized Study in patients with ANaplastic glioma of radiotherapy with Temozolomide versus nimustine hydrochloride（ACNU） followed by temozolomide
JCOG1303: Randomized phase III study for unresectable WHO Grade II diffuse astrocytoma with radiotherapy alone or chemoradiotherapy with temozolomide
Number of patients treated by external beam radiotherapy in 2017.
Total new patients 467
|1. Head and Neck cancers||102|
|2. Lung cancer/ Mediastinal tumor||100|
|3. Breast cancer||34|
|4. Esophageal cancer||82|
|5. Liver, bile duct and pancreas cancer||64|
|6. Uterine cancer||40|
|7. Genitourinary cancers||24|
|8. Lymphoma and leukemia||59|
|9. Colon, rectum and stomach cancer||30|
|10. Central nervous tumors||39|
Number of patients treated with specialized techniques.
|Intensity modulated radiation therapy||163pts|
|Intensity modulated radiation therapy for head and neck cancer||84pts|
|Intensity modulated radiation therapy for brain tumor||28pts|
|Stereotactic body radiotherapy for lung and liver tumor||34pts|
|Ir-192high-dose-rate brachytherapy for uterine cancer||22pts|
|Ir-192or Au-198 brachytherapy for oral cancer||12pts|
|I-131for thyroid cancer||84pts|